Lactobacillus acidophilus – LA02 (DSM 21717)

    Gastroenterology strain | Gut permeability, anti-inflammatory activity

    Characteristics

    FUNCTIONALITY
    Rebalance of intestinal microbiota

    Scientific support

    In vitro study
    Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J. Clin. Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (LA02, LPC00).

    Internal data in vitro on gut permeability protection and anti-inflammatory activity available upon request for LA02.


    Gastroenterology blend | IBS

    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus acidophilus – LA02 (DSM 21717)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    5 billion CFU + 5 billion CFU

    FUNCTIONALITY
    IBS • Reduction of gastro-intestinal discomfort • Reduction of inflammation

    Scientific support

    Human clinical trial
    Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106.

    In vitro study
    Nicola S. et al. Immunomodulation properties of Lactobacillus plantarum LP01 (LMG P-21021) and Lactobacillus acidophilus LA02 (DSM 21717) blend.

    Internal data in vitro on gut permeability and anti-inflammatory activity available upon request.


    Gynecology blend | Vaginal candidiasis

    • Lactobacillus acidophilus – LA02 (DSM 21717)
    • Lactobacillus fermentum – LF10 (DSM 19187)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1,2) 400 million CFU/strain/tablet + Carbon dioxide + FOS + Arabinogalactan

    FUNCTIONALITY
    Vaginal health • Inhibition of Candida strains • Innovative effervescent slow release tablet for enhanced delivery and activity of lactobacilli • Counteraction of Candida vulvovaginitis

    Scientific support

    Human clinical trials
    1) Vicariotto F. et al. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012; 46 Suppl:S73-80.
    2) Murina F. et al. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a Slow-release Vaginal Product be Useful for Prevention of Recurrent Vulvovaginal Candidiasis? J Clin Gastroenterol. 2014; 48:S102-105.

    In vitro study
    Deidda F. et al. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. J Clin Gastroenterol. 2016; 50:S171-S174.


    Urology strain | Kidney stones

    Characteristics

    FUNCTIONALITY
    Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

    Scientific support

    In vitro studies
    Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.

    + Internal data on anti-inflammatory and anti-oxidant properties available upon request on certain strains


    Gut-brain strain | Parkinson’s disease

    Scientific support

    Luca Magistrelli et al. Probiotics May Have Beneficial Effects in Parkinson’s Disease: In vitro Evidence. Front. Immunol., 07 May 2019